Taking aim at disease

February 16, 2024, 3:02PMNuclear NewsKristi Nelson Bumpus
ORNL radioisotope manufacturing coordinator Jillene Sennon-Greene places a shipment vial of actinium-225 inside the dose calibrator to confirm its activity is within customer specifications. (Photo: Carlos Jones/ORNL, DOE)

On August 2, 1946, 1 millicurie of the isotope carbon-14 left Oak Ridge National Laboratory, bound for the Barnard Free Skin and Cancer Hospital in St. Louis, Mo.

That tiny amount of the radioisotope was purchased by the hospital for use in cancer studies. And it heralded a new peacetime mission for ORNL, built just a few years earlier for the production of plutonium from uranium for the Manhattan Project.

To continue reading, log in or create a free account!

Related Articles

DOE, NRC prepare for government shutdown

October 1, 2025, 12:03PMNuclear News

The Department of Energy and the Nuclear Regulatory Commission will furlough thousands of employees and operate at reduced capacity under a government shutdown that started after midnight on...

Oklo breaks ground at INL on Aurora reactor

September 29, 2025, 6:25AMNuclear News

Following the same milestones from Aalo Atomics and Valar Atomics, Santa Clara, Calif.–based reactor start-up Oklo has become the third company participating in the Department of Energy’s...

NEDHO: A conversation with Seungjin Kim

September 24, 2025, 12:10PMNuclear News

Recently, Nuclear Engineering Department Heads Organization Chair Seungjin Kim talked with Nuclear News about NEDHO’s current condition, governmental funding for NEDHO and university...